|
流感病毒传染性IVR-228[H3N2]21/246
|
EA
|
21/246
|
咨询
|
1-4/12周
|
|
传染性B型流感病毒/新加坡/WUH4618/2021[B-维多利亚谱系]21/242
|
EA
|
21/242
|
咨询
|
1-4/12周
|
|
流感病毒传染性B/密歇根/1/2021[B/维多利亚谱系]21/244
|
EA
|
21/244
|
咨询
|
1-4/12周
|
|
流感病毒传染性CNIC-1909[H1N1]21/240
|
EA
|
21/240
|
咨询
|
1-4/12周
|
|
流感病毒传染性A/达尔文/6/2021[H3N2]21/212
|
EA
|
21/212
|
咨询
|
1-4/12周
|
|
WHO国际参考试剂破伤风抗毒素马用于絮凝试验21/230
|
EA
|
21/230
|
4988
|
1-4/12周
|
|
流感病毒传染性BVR-25[B-维多利亚谱系]21/216
|
EA
|
21/216
|
咨询
|
1-4/12周
|
|
流感病毒传染性A/达尔文/9/2021[H3N2]21/214
|
EA
|
21/214
|
咨询
|
1-4/12周
|
|
流感病毒传染性NIB-127[H3N2]21/226
|
EA
|
21/226
|
咨询
|
1-4/12周
|
|
流感病毒传染性NIB-126[H3N2]21/228
|
EA
|
21/228
|
咨询
|
1-4/12周
|
|
流感病毒传染性BX-97A[B-维多利亚谱系]21/192
|
EA
|
21/192
|
咨询
|
1-4/12周
|
|
流感病毒传染性X-361A[H3N2]21/190
|
EA
|
21/190
|
咨询
|
1-4/12周
|
|
流感病毒传染性IVR-227[H3N2]21/204
|
EA
|
21/204
|
咨询
|
1-4/12周
|
|
甲型流感病毒/香港/2671/201921/194
|
EA
|
21/194
|
咨询
|
1-4/12周
|
|
流感病毒传染性A/塔斯马尼亚/503/2020[H3N2]21/186
|
EA
|
21/186
|
咨询
|
1-4/12周
|
|
流感病毒传染性IVR-224[H3N2]21/196
|
EA
|
21/196
|
咨询
|
1-4/12周
|
|
流感病毒传染性X-353[H3N2]21/160
|
EA
|
21/160
|
咨询
|
1-4/12周
|
|
脑膜炎球菌荚膜W组多糖21/180
|
EA
|
21/180
|
4502
|
1-4/12周
|
|
2022年第1批西妥昔单抗体外生物活性国际标准21/170
|
EA
|
21/170
|
4988
|
1-4/12周
|
|
流感病毒传染性X-355B[H3N2]21/164
|
EA
|
21/164
|
咨询
|
1-4/12周
|
